TrialPsychopharmacology2020

CDP-choline and galantamine, a personalized α7 nicotinic acetylcholine receptor targeted treatment for the modulation of speech MMN indexed deviance detection in healthy volunteers: a pilot study.

Joelle Choueiry et al.PubMed ↗Publisher ↗

No numbers read from the abstract.